160 related articles for article (PubMed ID: 38233758)
1. Seamless phase 2/3 design for trials with multiple co-primary endpoints using Bayesian predictive power.
Yang J; Li G; Yang D; Wu J; Wang J; Gao X; Liu P
BMC Med Res Methodol; 2024 Jan; 24(1):12. PubMed ID: 38233758
[TBL] [Abstract][Full Text] [Related]
2. Accelerate vaccine development using seamless phase 2/3 trial designs.
Yang JY; Li GC; Yuan Y
Expert Rev Vaccines; 2024; 23(1):523-534. PubMed ID: 38682812
[TBL] [Abstract][Full Text] [Related]
3. An optimal Bayesian predictive probability design for phase II clinical trials with simple and complicated endpoints.
Guo B; Liu S
Biom J; 2020 Mar; 62(2):339-349. PubMed ID: 31402481
[TBL] [Abstract][Full Text] [Related]
4. Using dichotomized survival data to construct a prior distribution for a Bayesian seamless Phase II/III clinical trial.
Duputel B; Stallard N; Montestruc F; Zohar S; Ursino M
Stat Methods Med Res; 2023 May; 32(5):963-977. PubMed ID: 36919403
[TBL] [Abstract][Full Text] [Related]
5. Do we need to adjust for interim analyses in a Bayesian adaptive trial design?
Ryan EG; Brock K; Gates S; Slade D
BMC Med Res Methodol; 2020 Jun; 20(1):150. PubMed ID: 32522284
[TBL] [Abstract][Full Text] [Related]
6. Optimal timing for an accelerated interim futility analysis incorporating real world data.
Haine LMF; Murray TA; Koopmeiners JS
Contemp Clin Trials; 2024 May; 140():107489. PubMed ID: 38461938
[TBL] [Abstract][Full Text] [Related]
7. A randomized Bayesian optimal phase II design with binary endpoint.
Ding Y
J Biopharm Stat; 2023 Mar; 33(2):151-166. PubMed ID: 35793222
[TBL] [Abstract][Full Text] [Related]
8. Some design considerations incorporating early futility for single-arm clinical trials with time-to-event primary endpoints using Weibull distribution.
Waleed M; He J; Phadnis MA
Pharm Stat; 2021 May; 20(3):610-644. PubMed ID: 33565236
[TBL] [Abstract][Full Text] [Related]
9. Improving interim decisions in randomized trials by exploiting information on short-term endpoints and prognostic baseline covariates.
Van Lancker K; Vandebosch A; Vansteelandt S
Pharm Stat; 2020 Sep; 19(5):583-601. PubMed ID: 32248662
[TBL] [Abstract][Full Text] [Related]
10. BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints.
Zhou H; Lee JJ; Yuan Y
Stat Med; 2017 Sep; 36(21):3302-3314. PubMed ID: 28589563
[TBL] [Abstract][Full Text] [Related]
11. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
Schmidli H; Bretz F; Racine-Poon A
Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
[TBL] [Abstract][Full Text] [Related]
12. Using short-term endpoints to improve interim decision making and trial duration in two-stage phase II trials with nested binary endpoints.
Zocholl D; Kunz CU; Rauch G
Stat Methods Med Res; 2023 Sep; 32(9):1749-1765. PubMed ID: 37489267
[TBL] [Abstract][Full Text] [Related]
13. A novel Bayesian adaptive design incorporating both primary and secondary endpoints for randomized IIB chemoprevention study of women at increased risk for breast cancer.
Gajewski BJ; Kimler BF; Koestler DC; Mudaranthakam DP; Young K; Fabian CJ
Trials; 2022 Dec; 23(1):981. PubMed ID: 36471449
[TBL] [Abstract][Full Text] [Related]
14. Bayesian adaptive design for pediatric clinical trials incorporating a community of prior beliefs.
Wang Y; Travis J; Gajewski B
BMC Med Res Methodol; 2022 Apr; 22(1):118. PubMed ID: 35448963
[TBL] [Abstract][Full Text] [Related]
15. Sample size reestimation and Bayesian predictive probability for single-arm clinical trials with a time-to-event endpoint using Weibull distribution with unknown shape parameter.
Waleed M; He J; Phadnis MA
J Biopharm Stat; 2024 Jul; 34(4):469-487. PubMed ID: 37545144
[TBL] [Abstract][Full Text] [Related]
16. Beta spending function based on conditional power in group sequential design.
Ni S; Zhong Z; Jiang Z; Zhao Y; Wu J; Yu H; Bai J
Biom J; 2024 Apr; 66(3):e2300094. PubMed ID: 38581099
[TBL] [Abstract][Full Text] [Related]
17. Epistemic uncertainty in Bayesian predictive probabilities.
Liu CC; Yu RX
J Biopharm Stat; 2024 May; 34(3):394-412. PubMed ID: 37157818
[TBL] [Abstract][Full Text] [Related]
18. Trial monitoring via a futility criterion for interim results on a count data endpoint and a continuous endpoint.
Quan H; Kang T; Fan C; Lu X; Chen X; Luo X; Wei L
Contemp Clin Trials; 2021 Apr; 103():106316. PubMed ID: 33571688
[TBL] [Abstract][Full Text] [Related]
19. Sample size re-estimation in Phase 2 dose-finding: Conditional power versus Bayesian predictive power.
Liu Q; Hu G; Ye B; Wang S; Wu Y
Pharm Stat; 2023 Mar; 22(2):349-364. PubMed ID: 36418025
[TBL] [Abstract][Full Text] [Related]
20. Over-accrual in Bayesian adaptive trials with continuous futility stopping.
Barrado LG; Burzykowski T
Clin Trials; 2023 Jun; 20(3):252-260. PubMed ID: 36803007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
